[{"id":"059be10f-2a45-47c2-978f-ca17df6ee6cf","acronym":"ICP-CL-00301","url":"https://clinicaltrials.gov/study/NCT03758664","created_at":"2021-01-18T18:28:29.537Z","updated_at":"2024-07-02T16:36:07.705Z","phase":"Phase 1/2","brief_title":"Clinical Study of ICP-192 in Solid Tumors Patients","source_id_and_acronym":"NCT03758664 - ICP-CL-00301","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 translocation","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gunagratinib (ICP-192)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 12/19/2018","start_date":" 12/19/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-07-06"},{"id":"d4d894ac-2658-4499-8ad7-5be03852e67a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173142","created_at":"2021-12-29T13:53:45.797Z","updated_at":"2025-02-25T14:52:10.343Z","phase":"Phase 1/2","brief_title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05173142","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 01/22/2022","start_date":" 01/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-03-08"}]